Patents by Inventor Marc Ostermeier
Marc Ostermeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170369855Abstract: The present invention provides methods of systems and methods of site specific methylation.Type: ApplicationFiled: December 24, 2015Publication date: December 28, 2017Inventors: Carl NOVINA, Glenna MEISTER, Marc OSTERMEIER, Tina XIONG
-
Publication number: 20170058268Abstract: The present invention provides an in vitro directed evolution selection system to create modified methyltransferases which improve methyltransferase specificity and use it to optimize and provide fusion proteins comprising a zinc finger methyltransferase derived from M.SssI. The resulting fusion proteins show increased target methylation specificity and greatly decreased non-target methylation compared to wild-type enzyme activity. Methods of use of such fusion proteins in both prokaryotic and eukaryotic cells are also provided.Type: ApplicationFiled: March 11, 2015Publication date: March 2, 2017Inventors: Marc Ostermeier, Brian Chaikind
-
Patent number: 9469841Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.Type: GrantFiled: May 30, 2014Date of Patent: October 18, 2016Assignee: The Johns Hopkins UniversityInventors: Marc A. Ostermeier, Chapman M. Wright
-
Patent number: 9273319Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.Type: GrantFiled: February 28, 2013Date of Patent: March 1, 2016Assignee: The Johns Hopkins UniversityInventor: Marc Ostermeier
-
Publication number: 20140273217Abstract: The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Marc A. Ostermeier, Chapman M. Wright
-
Patent number: 8592192Abstract: A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from Pyrococcus furiosus (PfMBP). Unlike conventional protein stabilization methods that employ mutations and recombinations, the inventive approach does not require any modification on a target protein except for its connection with a hyperthermophilic protein scaffold. For that reason, target protein substrate specificity was largely maintained, which is often modified through conventional protein stabilization methods. The insertion was achieved through gene fusion by recombinant DNA techniques.Type: GrantFiled: March 5, 2010Date of Patent: November 26, 2013Assignee: Polytechnic Institute of NYUInventors: Jin Ryoun Kim, Brennal Pierre, Marc Ostermeier, Chung-Sei Kim
-
Publication number: 20130230925Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.Type: ApplicationFiled: February 28, 2013Publication date: September 5, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Marc Ostermeier
-
Patent number: 8492122Abstract: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches and expression vectors and host cells for expressing the switches are also provided.Type: GrantFiled: March 10, 2003Date of Patent: July 23, 2013Assignee: The Johns Hopkins UniversityInventor: Marc Ostermeier
-
Patent number: 8338138Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.Type: GrantFiled: January 28, 2005Date of Patent: December 25, 2012Assignee: The John Hopkins UniversityInventors: Marc A. Ostermeier, Gurkan Guntas
-
Patent number: 7820413Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.Type: GrantFiled: February 19, 2008Date of Patent: October 26, 2010Assignee: The Penn State Research FoundationInventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
-
Publication number: 20100227374Abstract: A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from Pyrococcus furiosus (PfMBP). Unlike conventional protein stabilization methods that employ mutations and recombinations, the inventive approach does not require any modification on a target protein except for its connection with a hyperthermophilic protein scaffold. For that reason, target protein substrate specificity was largely maintained, which is often modified through conventional protein stabilization methods.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Inventors: Jin Ryoun Kim, Brennal Pierre, Marc Ostermeier, Chung-Sei Kim
-
Publication number: 20090005266Abstract: The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.Type: ApplicationFiled: January 28, 2005Publication date: January 1, 2009Applicant: The Johns Hopkins UniversityInventors: Marc A. Ostermeier, Gurkan Guntas
-
Publication number: 20080227650Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.Type: ApplicationFiled: February 19, 2008Publication date: September 18, 2008Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
-
Publication number: 20080227659Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.Type: ApplicationFiled: February 19, 2008Publication date: September 18, 2008Inventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
-
Patent number: 7332308Abstract: A series of methods that utilize the incremental truncation of nucleic acids are described to create a plurality of modified nucleic acids and hybrid polypeptides. A plurality of substantially all possible single base-pair deletions of a given nucleic acid sequence is created. A method of making shuffled incremental truncated nucleic acids, which is independent of nucleic acid sequence homology, is also described. These methods can be used in protein engineering, protein folding, protein evolution, and the chemical synthesis of novel hybrid proteins and polypeptides.Type: GrantFiled: November 15, 2000Date of Patent: February 19, 2008Assignee: The Penn State Research FoundationInventors: Stephen J. Benkovic, Marc Ostermeier, Stefan Lutz, Andrew E. Nixon
-
Patent number: 6027888Abstract: Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.Type: GrantFiled: April 4, 1997Date of Patent: February 22, 2000Assignee: Board of Regents, The University of Texas SystemInventors: George Georgiou, Marc Ostermeier